Aralez Pharmaceuticals Inc.’s (ARLZ) Yosprala, which failed to win over U.S. regulators in 2014, is trying its luck a third time. The company is seeking approval of Yosprala for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. Yosprala was issued a Complete Response Letter by the FDA in April 2014, with deficiencies at a manufacturing facility of a third party supplier of an active ingredient blamed for the action. The new drug application for Yosprala resubmitted in July 2014 was also sent back to the drawing board in December of that year due to deficiencies at the manufacturing facility.Addressing the concerns raised by the FDA, Aralez submitted the NDA for Yosprala again in March of this year, and is waiting the FDA ruling, which is expected on September 14, 2016.Will Yosprala make it to the finish line at least this time around?